SCHEMBL3201350

SCHEMBL3201350

Cc1ccc(SCNc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.57
NOD1 Q9Y239 3/20 0.57
MEN1 O00255 3/20 0.57
HTT P42858 2/20 0.57
RAB9A P51151 3/20 0.56
GALR3 O60755 1/20 0.56
NR2F2 P24468 1/20 0.56
DRD2 P14416 4/20 0.55
LMNA P02545 3/20 0.55
TBXA2R P21731 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
ALDH1A1 P00352 3/20 0.55
NPSR1 Q6W5P4 3/20 0.55
KDM4E B2RXH2 2/20 0.55
NOD2 Q9HC29 2/20 0.55
NPC1 O15118 2/20 0.53
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3185645 0.92 ALDH1A1 (0.57) KMT2AMEN1HTTRAB9ALMNA
SCHEMBL20715451 0.80 NOD2 (0.67) KMT2ANOD1MEN1HTTRAB9A
SCHEMBL1170123 0.80 SMN1; SMN2 (0.74) KMT2ANOD1MEN1HTTRAB9A
SCHEMBL27898258 0.79 ALDH1A1 (0.74) KMT2AMEN1HTTRAB9ADRD2
SCHEMBL26350886 0.79 ALDH1A1 (0.74) KMT2AMEN1HTTRAB9ADRD2
SCHEMBL27898218 0.78 ALDH1A1 (0.76) KMT2ANOD1MEN1HTTRAB9A
SCHEMBL27915822 0.78 ALDH1A1 (0.76) KMT2ANOD1MEN1HTTRAB9A
SCHEMBL22726434 0.76 ALDH1A1 (0.62) KMT2ANOD1MEN1HTTRAB9A
SCHEMBL13559765 0.75 MAPT (0.62) KMT2ANOD1MEN1HTTRAB9A
SCHEMBL17481607 0.74 NPC1 (0.70) KMT2AMEN1HTTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2010-02-11 US disclosed
EP-2041096-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL- CONDUCTANCE CALCIUM-ACTIVATED POTATIUM CHANNELS NeuroSearch AS (DK) 2009-04-01 EP disclosed
WO-2008003752-A1 2 -AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL - CONDUCTANCE CALCIUM -ACT IVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 KMT2A 500/4885NOD1 992/4885MEN1 3173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.